Stipple Bio and Lonza Agree to Focus on Advancing Oncology ADC Therapies

This collaboration between Stipple Bio and Lonza combines the former’s epitope discovery capabilities with the latter’s GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, and a toxSYN linker payload.

The post Stipple Bio and Lonza Agree to Focus on Advancing Oncology ADC Therapies appeared first on GEN - Genetic Engineering and Biotechnology News.